Viking Therapeutics reports VK2735 maintenance trial keeps up to 97% of weight loss with every-other-week dosing

PUBT · 1d ago
Viking Therapeutics reports VK2735 maintenance trial keeps up to 97% of weight loss with every-other-week dosing
  • Viking Therapeutics reported positive topline results from a maintenance study of obesity drug candidate VK2735, following an earlier weekly induction phase.
  • Findings showed weight loss could be maintained when dosing shifted to less frequent schedules, supporting broader use beyond weekly injections.
  • Weekly dosing over a longer period continued to drive additional weight reduction, suggesting durability without an apparent flattening of effect.
  • Safety during maintenance looked favorable, with gastrointestinal side effects broadly comparable to placebo and low treatment discontinuations.
  • Results have already been released; an oral-maintenance component is planned for a future part 2 of the study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609220705PR_NEWS_USPR_____LA53571) on September 22, 2026, and is solely responsible for the information contained therein.